Peer-reviewed veterinary case report
TGF-beta levels linked to tumor growth and spread in malignant dog
By Carvalho, Maria Isabel et al.·Published in The veterinary quarterly·2024·MVET Research in Veterinary Medicine. Faculty of Veterinary Medicine·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: TGFβ in malignant canine mammary tumors: relation with angiogenesis, immunologic markers and prognostic role.
- Species:
- dog
Plain-English summary
A study looked at 67 dogs with malignant mammary tumors and found that high levels of a protein called TGF-β were linked to more severe tumor characteristics, such as skin ulcers and the presence of cancer in lymph nodes. Dogs with these high levels of TGF-β had a shorter survival time, especially if they also had high levels of certain immune markers. This suggests that TGF-β and related immune cells could be important for understanding how these tumors grow and might be targets for future treatments.
People also search for: dog mammary tumor prognosis · canine breast cancer treatment · high TGF-beta in dogs
Abstract
Transforming growth factor-β (TGFβ) and FoxP3 regulatory T cells (Treg) are involved in human breast carcinogenesis. This topic is not well documented in canine mammary tumors (CMT). In this work, the tumoral TGFβ expression was assessed by immunohistochemistry in 67 malignant CMT and its correlation to previously determined FoxP3, VEGF, and CD31 markers and other clinicopathologic parameters was evaluated. The high levels of TGFβ were statistically significantly associated with skin ulceration, tumor necrosis, high histological grade of malignancy (HGM), presence of neoplastic intravascular emboli and presence of lymph node metastases. The observed levels of TGFβ were positively correlated with intratumoral FoxP3 (strong correlation), VEGF (weak correlation) and CD31 (moderate correlation). Tumors that presented a concurrent high expression of TGFβ/FoxP3, TGFβ/VEGF, and TGFβ/CD31 markers were statistically significantly associated with parameters of tumor malignancy (high HGM, presence of vascular emboli and nodal metastasis). Additionally, shorter overall survival (OS) time was statistically significantly associated with tumors with an abundant TGFβ expression and with concurrent high expression of TGFβ/FoxP3, TGFβ/VEGF, and TGFβ/CD31. The presence of lymph node metastasis increased 11 times the risk of disease-related death, arising as an independent predictor of poor prognosis in the multivariable analysis. In conclusion, TGFβ and Treg cells seem involved in tumor progression emerging as potential therapeutic targets for future immunotherapy studies.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/39165025/